{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Previously+Untreated+Gastric+Cancer&page=2", "query": { "condition": "Previously Untreated Gastric Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Previously+Untreated+Gastric+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T18:33:47.898Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05052801", "title": "Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Bemarituzumab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 547, "start_date": "2022-03-07", "completion_date": "2026-04-26", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-06-10T18:33:47.898Z", "location_count": 16, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Cerritos, California + 13 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05052801" }, { "nct_id": "NCT03343301", "title": "A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Cancer", "Gastrointestinal Cancer Metastatic", "Gastric Cancer" ], "interventions": [ { "name": "Bemarituzumab", "type": "BIOLOGICAL" }, { "name": "Modified FOLFOX6", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Five Prime Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2017-11-30", "completion_date": "2019-01-31", "has_results": true, "last_update_posted_date": "2024-02-28", "last_synced_at": "2026-06-10T18:33:47.898Z", "location_count": 7, "location_summary": "Tucson, Arizona • Greenbrae, California • Whittier, California + 4 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03343301" }, { "nct_id": "NCT00020787", "title": "Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "G17DT Immunogen", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2001-07", "completion_date": "2002-12", "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-06-10T18:33:47.898Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020787" }, { "nct_id": "NCT05111626", "title": "Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Bemarituzumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 515, "start_date": "2022-03-14", "completion_date": "2027-01-29", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-06-10T18:33:47.898Z", "location_count": 37, "location_summary": "Phoenix, Arizona • Cerritos, California • Downey, California + 31 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Downey", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05111626" }, { "nct_id": "NCT00017212", "title": "DX-8951f in Treating Patients With Metastatic Stomach Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "exatecan mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-04", "completion_date": "2003-09", "has_results": false, "last_update_posted_date": "2012-05-16", "last_synced_at": "2026-06-10T18:33:47.898Z", "location_count": 5, "location_summary": "Long Beach, California • Denver, Colorado • Dallas, Texas + 2 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00017212" }, { "nct_id": "NCT00382720", "title": "Docetaxel and Oxaliplatin in Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stomach Neoplasms" ], "interventions": [ { "name": "Docetaxel + Oxaliplatin", "type": "DRUG" }, { "name": "Docetaxel + Oxaliplatin + 5-FU", "type": "DRUG" }, { "name": "Docetaxel + Oxaliplatin + Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2006-09", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2013-01-07", "last_synced_at": "2026-06-10T18:33:47.898Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00382720" }, { "nct_id": "NCT03675737", "title": "Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stomach Neoplasms" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "Placebo for Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1579, "start_date": "2018-11-08", "completion_date": "2025-03-03", "has_results": true, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-06-10T18:33:47.898Z", "location_count": 10, "location_summary": "Los Angeles, California • Orange, California • Miami, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03675737" }, { "nct_id": "NCT01611857", "title": "Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Solid Tumour", "Gastroesophageal Cancer" ], "interventions": [ { "name": "Tivantinib", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2012-07", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-11-23", "last_synced_at": "2026-06-10T18:33:47.898Z", "location_count": 9, "location_summary": "New Haven, Connecticut • Fort Myers, Florida • Sarasota, Florida + 6 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01611857" }, { "nct_id": "NCT01355302", "title": "E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Solid Tumors", "Previously Untreated Gastric Cancer" ], "interventions": [ { "name": "E7050", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2011-11", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2017-05-15", "last_synced_at": "2026-06-10T18:33:47.898Z", "location_count": 9, "location_summary": "Tucson, Arizona • Plantation, Florida • Chicago, Illinois + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Plantation", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01355302" }, { "nct_id": "NCT03694522", "title": "A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "Bemarituzumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Modified FOLFOX6", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Five Prime Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2018-09-14", "completion_date": "2022-05-13", "has_results": true, "last_update_posted_date": "2024-02-28", "last_synced_at": "2026-06-10T18:33:47.898Z", "location_count": 29, "location_summary": "Tucson, Arizona • Greenbrae, California • Sacramento, California + 23 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03694522" } ] }